EUVIMEDEUVIMED entdecken
Crossref

Endophthalmitis After Dexamethasone Implant

Maryam Eghtedari iD, Zelia Chiu, Fatemeh Shams iD, Penelope J Allen, Rosie C H Dawkins iD

Clinical & Experimental Ophthalmology · 2026

DOI: 10.1111/ceo.70066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2026. Verfasst von Maryam Eghtedari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vitreo-Retinal Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Dexamethasone, Endophthalmitis, Glucocorticoids, Eye Infections, Bacterial. Die Arbeit nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The dexamethasone intravitreal implant is used to treat sight‐threatening retinal disorders. Endophthalmitis is a serious complication of intravitreal injections and requires urgent intervention. Recent evidence demonstrates that the dexamethasone implant has higher endophthalmitis rates than some intravitreal injections. We present a large, prospective, state‐wide analysis.

Methods

The Victorian Endophthalmitis Registry prospectively identified all dexamethasone implant‐related endophthalmitis cases from January 2018 to June 2024 in Victoria, Australia, managed at the Royal Victorian Eye and Ear Hospital, a state‐wide service. The Pharmaceutical Benefits Schedule Item Reports available on the Medicare Australia database were used to determine the number of dexamethasone implants in Victoria, Australia, to calculate the incidence rate of dexamethasone implant‐related endophthalmitis.

Results

Fifteen incidences from 9457 implants resulted in endophthalmitis (rate = 0.16%, 1 in 630 injections). All cases received inpatient care with an aqueous and vitreous tap, intravitreal vancomycin, and ceftazidime. Fourteen cases (93%, n = 15) underwent surgical intervention, including 13 cases of vitrectomy (87%, n = 15). A causative pathogen was isolated in 86.7% of vitreous samples ( n = 13/15), with Staphylococcus epidermidis being the most common, found in seven eyes (46.7%, n = 15). Three eyes (20%, n = 15) underwent enucleation. The remaining 12 eyes had a mean follow‐up visual acuity of Snellen 6/27 (logMAR 0.65 ± 0.43).

Conclusions

The rate of dexamethasone implant‐related endophthalmitis is 0.16% which is higher than other intravitreal injections reported in the literature, with considerably poor visual outcomes. The vitreous diagnostic samples are culture‐positive in 87% of cases (13/15), with 46.7% (7/15) isolating Staphylococcus epidermidis .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneEndophthalmitisGlucocorticoidsEye Infections, BacterialHumansDrug ImplantsIncidenceProspective StudiesFemaleIntravitreal InjectionsMaleAgedVictoriaAnti-Bacterial AgentsRegistriesVitreous BodyAged, 80 and overBacteria

Stichwörter der Autor:innen

dexamethasone (DEX) implantendophthalmitisintravitreal injection

Substanzen

DexamethasoneGlucocorticoidsDrug ImplantsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Vitreo-Retinal Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.
  • Vitreo-Retinal Unit, St Helens Hospital, St Helens, UK.
  • Centre for Eye Research Australia, Melbourne, Victoria, Australia.
  • The University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Maryam Eghtedari, Fatemeh Shams, Rosie C H Dawkins

Zitieren

APA

Eghtedari, M., Chiu, Z., Shams, F., Allen, P. J., & Dawkins, R. C. H. (2026). Endophthalmitis After Dexamethasone Implant. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.70066

Vancouver

Eghtedari M, Chiu Z, Shams F, Allen PJ, Dawkins RCH. Endophthalmitis After Dexamethasone Implant. Clinical & Experimental Ophthalmology. 2026. doi:10.1111/ceo.70066

BibTeX
@article{Eghtedari2026,
  author = {Eghtedari, Maryam and Chiu, Zelia and Shams, Fatemeh and Allen, Penelope J and Dawkins, Rosie C H},
  title = {Endophthalmitis After Dexamethasone Implant},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2026},
  doi = {10.1111/ceo.70066}
}
Kostenlos starten →